CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of hematologic cancers.
  
  LEARNING OBJECTIVES

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences between commercially available and investigational products.
  • Appraise existing efficacy data from clinical trials of approved CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Appreciate available data documenting the activity of CAR T-cell therapy targeting BCMA in multiple myeloma (MM), and use this knowledge to counsel patients who may be appropriate for this approach within or outside of a protocol setting.
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 and CD3 in patients with B-cell lymphomas.
  • Review the biologic rationale for and available efficacy findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and consider the potential clinical role of these agents.
  • Recognize common adverse events associated with approved and investigational CAR T-cell therapies and bispecific T-cell-engaging antibodies, and implement strategies to educate patients who are eligible for these treatments about the potential for complications.
  • Recall ongoing research evaluating bispecific antibodies or CAR T-cell-based approaches for various B-cell lymphomas, chronic lymphocytic leukemia and MM, and counsel appropriate patients regarding the potential benefits of trial participation.

  CE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
  CME credit is no longer available for this issue
  
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Audio Program: This NCPD activity consists of an audio component.
  NCPD credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
  
  All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
  
  This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
  
  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
  
  FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  
  
  Ajai Chari, MD
  Professor of Medicine (Hematology and Medical Oncology)
  Icahn School of Medicine at Mount Sinai
  Director, Clinical Research, Multiple Myeloma Program
  Associate Medical Director
  The Tisch Cancer Institute Clinical Trials Office
  New York, New York
  
  Advisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Oncoceutics Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  Ian W Flinn, MD, PhD
  Director of Lymphoma Research Program
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements (to Sarah Cannon Research Institute): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Secura Bio, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Verastem Inc, Vincerx Pharma, Xencor; Research Grants (to Sarah Cannon Research Institute): 2seventy bio, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bio-Path Holdings Inc, Bristol-Myers Squibb Company, CALGB, Calibr, Celgene Corporation, City of Hope National Medical Center, Constellation Pharmaceuticals, CTI BioPharma Corp, Curis Inc, Epizyme Inc, Fate Therapeutics, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, TCR2 Therapeutics, Tessa Therapeutics, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc.
  
  Nikhil C Munshi, MD
  Kraft Family Chair
  Director of Basic and Correlative Science
  Jerome Lipper Multiple Myeloma Center
  Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Legend Biotech, Novartis, Oncopeptides, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Stock Ownership: C4 Therapeutics.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Associate Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose:
  Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Genentech, a member of the Roche Group, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: August 31, 2022
  Expiration date: August 31, 2023